BIOA vs SGMT
BIOA: Clinical-stage biotech targeting aging biology to develop novel small-molecule therapeutics for metabolic and cardiovascular diseases, led by brain-penetrant NLRP3 inhibitor BGE-102. SGMT: Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other metabolic diseases.
Side-by-side fundamentals
| Metric | BIOA | SGMT | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $24.85 | $7.31 | |
| Market cap as of 2026-07-31 | $986M | $447M | |
| PEG as of 2026-07-31 | -0.50 | n/a | |
| Net margin as of 2026-07-31 | -871.8% | -1393.8% | BIOA higher |
| Operating margin as of 2026-07-31 | -985.9% | -1537.0% | BIOA higher |
| ROE as of 2026-07-31 | -29.4% | -37.6% | BIOA higher |
| ROA as of 2026-07-31 | -27.3% | -35.5% | BIOA higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | SGMT lower |
| Revenue growth (YoY) as of 2026-07-31 | +91.0% | n/a | |
| Beta as of 2026-07-31 | 0.96 | 1.89 | |
| 1-year return as of 2026-07-30 close | +462.2% | -17.8% | BIOA higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.